<DOC>
	<DOCNO>NCT01081600</DOCNO>
	<brief_summary>HSP90 inhibition potentially new target drug modality treatment HER2 positive , trastuzumab refractory breast cancer . Little known pharmacodynamics HSP90 inhibitor vivo , non-invasive PET/CT imaging xenograft mouse model could visualize quantify HER2 reduction AUY922 treatment 89Zr-trastuzumab PET imaging . Two dose 50 mg/kg AUY922 result decrease HER2 expression approximately 50 % , quantify 6 day last administration AUY922 . Visualizing HER2 expression breast cancer patient early follow HSP90 inhibition mean 89Zr-trastuzumab PET , likely provide insight early vivo effect HSP90 inhibition could potentially support patient tailor therapy .</brief_summary>
	<brief_title>89Zr-trastuzumab PET Imaging Effect HSP90 Inhibition</brief_title>
	<detailed_description>This study design side study multicenter , international phase I-II trial HSP90 inhibitor AUY922 ( protocol CAUY922A2101 ) , part biomarker assessment . In protocol CAUY922A2101 , section 4 , design phase I-II trial described ( p36 , 37 ) . Briefly , dose-escalation study perform accord phase I design . This part follow dose-expansion study accord phase II design . In latter part , breast cancer patient enrol either refractory hormone- trastuzumab treatment ( treatment arm , n=40 patient ) . Patients HER2 positive , trastuzumab refractory breast cancer , receive 89Zr-trastuzumab PET scan part present side study protocol , perform collaboration Royal Marsden Hospital ( United Kingdom ) . To end , 89Zr-trastuzumab PET scan perform ( baseline ) treatment HSP90 inhibitor AUY922 , describe . A minimum six patient need evaluate whether 89Zr-trastuzumab PET scan use detection decrease HER2 expression , induce HSP90 inhibition .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients HER2 positive , trastuzumab ( lapatinib ) refractory breast cancer Participation phase III trial HSP90 inhibitor AUY922 ( exclusion criterion study AUY922 describe protocol CAUY922A2101 . No participation phase III trial HSP90 inhibitor AUY922 ( CAUY922A2101 . Clinical trial . NCT00526045A )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Heat shock protein</keyword>
	<keyword>breast cancer</keyword>
	<keyword>PET image</keyword>
	<keyword>trastuzumab</keyword>
</DOC>